Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VCH-759 (BCH-27759)
VCH-759 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| VCH-759 (BCH-27759) | DRUG | - |
Inclusion Criteria: * 18 to 60 years of age * Body mass index (BMI) ≤ 30 * No evidence of cirrhosis or have liver fibrosis corresponding to Metavir Stages 0 to 3 * Subject's liver disease is stable (i.e., stable ALT and AST) * Serologic evidence of chronic hepatitis C-infection (anti-HCV in serum) ...
VCH-759 is an investigational small molecule developed for the treatment of chronic hepatitis C infection. It was studied in a Phase 1 proof-of-concept trial in adults with chronic hepatitis C. VCH-759 has not been approved for any indication and remains in clinical development.
VCH-759 is being developed by Vertex Pharmaceuticals Incorporated, which trades on the Nasdaq under the ticker VRTX. Vertex sponsored the Phase 1 proof-of-concept study of VCH-759 in chronic hepatitis C infection.
VCH-759 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. VCH-759 is investigational and has not been approved by the FDA for chronic hepatitis C or any other indication.
VCH-759 has been studied in one completed Phase 1 trial, NCT00389298, titled a proof-of-concept study of VCH-759 for the treatment of hepatitis C infection. The trial enrolled 36 male participants aged 18 years and older in Canada and was randomized and double blind.
Yes. VCH-759 is also known as BCH-27759, so both names refer to the same investigational compound for chronic hepatitis C. The primary name used in its clinical trial record is VCH-759.